CellCept Continues its Double Digit Growth
CellCept (mycophenolate mofetil), the world’s most widely used immunosuppressant medication and the cornerstone of treatment to prevent organ rejection in patients with solid organ transplants, continued its revenue growth despite loss of market exclusivity in certain countries. The main contributions to growth came from the United States (15%) and Europe (12%). Improved survival of transplant patients means that they are taking immunosuppressant therapy for longer, and this is reflected in a steady increase in prescriptions for CellCept.